Proposed changes to ABPI code of practice could hurt smaller firms, warns EMIG - update
This article was originally published in SRA
Proposed changes to the Association of the British Pharmaceutical Industry code of practice, now out for consultation, could help improve transparency in the pharmaceutical industry1. But plans to limit branded giveaways to healthcare professionals could disproportionately hurt smaller firms, making the code "unfit for purpose", warns the Ethical Medicines Industry Group, EMIG2.
You may also be interested in...
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.
Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.